Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-StageKidney Disease Attributed to Focal Segmental Glomerulosclerosis (FSGS)
A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-StageKidney Disease Attributed to Immunoglobulin A Nephropathy (IgAN)
A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-Stage Kidney Disease Attributed to Immunoglobulin A Nephropathy
A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-Stage Kidney Disease Attributed to Focal Segmental Glomerulosclerosis (FSGS)
IgA Nephropathy (IgAN) In Adults: A Retrospective Analysis Of US Prevalence And Impacts OfProteinuria And Kidney Function Decline On Healthcare Resource Utilization (HRU) And Costs
Focal Segmental Glomerulosclerosis (FSGS) In Adults: A Retrospective Analysis Of USPrevalence And Impacts Of Proteinuria And Kidney Function Decline On Healthcare ResourceUtilization (HRU) And Costs
IgA Nephropathy (IgAN) In Adults: A Retrospective Analysis Of US Prevalence And Impacts OfProteinuria And Kidney Function Decline On Healthcare Resource Utilization (HRU) And Costs
Focal Segmental Glomerulosclerosis (FSGS) In Adults: A Retrospective Analysis Of US PrevalenceAnd Impacts Of Proteinuria And Kidney Function Decline On Healthcare Resource Utilization (HRU)And Costs
Sparsentan, the dual endothelin angiotensin receptor antagonist(DEARA), attenuates albuminuria and protects from thedevelopment of renal injury to a greater extent than losartan inthe gddY mouse model of IgA nephropathy; a 16-week study
Sparsentan Protects the GlomerularBasement Membrane and Glycocalyx, andAttenuates Proteinuria in a Rat Model ofFocal Segmental Glomerulosclerosis (FSGS)
Baseline Characteristics of PatientsEnrolled in the Ongoing Phase 3Randomized, Double-Blind, Active-Control Trial of Sparsentan for theTreatment of Focal SegmentalGlomerulosclerosis (DUPLEX)
Baseline Characteristics of PatientsEnrolled in the Ongoing Phase 3Randomized, Double-Blind, Active-Control Trial of Sparsentan for theTreatment of Immunoglobulin ANephropathy (PROTECT)